Lista de obras -

Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial

artículo científico publicado en 2010

Age is a prognostic factor even among patients with multiple myeloma younger than 66 years treated with high-dose melphalan: the IFM experience on 2316 patients

artículo científico publicado en 2014

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

artículo científico publicado en 2011

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience

artículo científico publicado en 2013

Development and Validation of a Cytogenetic Prognostic Index Predicting Survival in Multiple Myeloma

artículo científico publicado en 2019

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.

artículo científico publicado en 2009

Impact of renal impairment on outcomes with lenalidomide and dexamethasone treatment in the FIRST trial, a randomized, open-label phase 3 trial in transplant-ineligible patients with multiple myeloma

artículo científico publicado en 2015

Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du Myélome

article

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma

scientific article published on 24 September 2018

Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial

artículo científico publicado en 2014

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results

artículo científico publicado en 2015

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.

artículo científico publicado en 2018

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

scientific article published on 11 October 2016

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

artículo científico publicado en 2012

The translocation t(4;14) can be present only in minor subclones in multiple myeloma